Erica Ollmann Saphire appointed president and CEO of La Jolla Institute for Immunology
Dr. Erica Ollmann Saphire
Dr. Saphire will become La Jolla Institute’s fifth president when she formally begins her term on September 1, 2021. She will succeed current LJI President Mitchell Kronenberg, who has successfully led the organization for the past 18 years.
“I am deeply honored to be asked to carry La Jolla Institute forward and lead such an exceptional group of immunologists and staff,” said Dr. Saphire. “LJI shines as one of the top immunology research organizations globally. I am excited to build on the Institute’s tremendous legacy of scientific excellence and tackle humanity’s most pressing health challenges.”
Grand Prize Winners Selected in $6M XPRIZE Rapid Covid Testing Competition to Create Fast, Frequent, Cheap, and Easy-to-Use Solutions
Dr. Rick Bright, Ph.D., Immunology and Molecular Pathogenesis
Shawna Butler, R.N. M.D.A., Nurse Economist
Dr. Charity Dean, CEO and Co-Founder, The Public Health Company
Dr. Paul Drain, Associate Professor, Departments of Global Health, Medicine and Epidemiology at the University of Washington
Dr. Anita Goel, Physicist and Physician, Chairman and CEO, Nanobiosym
Dr. Michael Mina, Physician-Scientist and Assistant Professor, Epidemiology and Immunology and Infectious Diseases at the Harvard School of Public Health
Dr. Anne Wyllie, Associate Research Scientist, Yale School of Public Health
La Jolla Institute for Immunology research leads to promising therapy for type 1 diabetes - kusi.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kusi.com Daily Mail and Mail on Sunday newspapers.
Translational research results in promising combination therapeutic candidate for type 1 diabetes
Translational research led by scientists at La Jolla Institute for Immunology (LJI) has resulted in a promising combination therapeutic candidate for adults with recent-onset type 1 diabetes.
The combination therapy was recently tested in a randomised, double-blind, placebo- controlled, phase 2 trial run and funded by pharmaceutical company Novo Nordisk. The results, published recently in
The Lancet Diabetes and Endocrinology, point to a potential way to treat the autoimmune disease without leaving the body vulnerable to infectious disease.
The therapeutic candidate combines anti-IL-21 antibody with the diabetes drug liraglutide. This two-pronged approach is based on research findings from the lab of LJI Professor Matthias von Herrath, M.D., who also serves as vice president and senior medical officer, Global Chief Medical Office, at Novo Nordisk.